Mankind Pharma looks set to ride India’s growing demand for healthcare, helped by a fast integration of a recent deal, stronger consumer brands, and a deeper push into treatments for long-term illnesses like diabetes and obesity. But heavy dependence on India, rising costs, and tougher rules could make it harder to protect profits as competition heats up.Read more
Mankind Pharma is leaning into long-term treatments and fast-growing consumer health brands, with more sales moving online and into modern retail—changes that could make its growth steadier over time. The big catch is that it relies heavily on India and faces cost and regulatory pressure, so the path to better profits may not be smooth.Read more
Key Takeaways Reliance on low-margin domestic generics and regulatory shifts risks eroding margins and threatens long-term profit sustainability. Limited global presence and lag in digital healthcare adoption expose the company to heightened market and competitive vulnerabilities.Read more
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
